`
`
`
` DEPARTMENT OF HEALTH & HUMAN SERVICES
`
`
`
`
`
`
`Public Health Service
`
`Food and Drug Administration
`
`Rockville, MD 20857
`
`
`
`
`
`
`
`
`
`
`
`
`
`NDA 21-572/S-021
`
`
`Cubist Pharmaceuticals, Inc.
`Attention: Karen L. Drake, Esquire
`Senior Director, Regulatory Affairs
`
`65 Hayden Avenue
`Lexington, MA 02421
`
`
`Dear Ms. Drake:
`
`
`Please refer to your supplemental new drug application dated June 27, 2008 received June 30, 2008,
`
`submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for CUBICIN®
`
`
`(daptomycin for injection).
`
`
`We acknowledge receipt of your submission dated September 17, 2008, and your electronic mail
`correspondence dated February 6, 2009.
`
`
`This “Changes Being Effected in 30 days” supplemental new drug application provides for revisions to
`the “Preparation of CUBICIN® for Administration” section of the package insert. Specifically, a new
`been added advising that CUBICIN® should not be used in conjunction with
`paragraph has
`ReadyMED® e
`lastomeric infusion pumps.
`
`
`
` our review of this application as amended, and it is approved effective on the date of We completed
`
`use as recommended in the agreed-upon labeling text, and with the minor editorial this letter, for
`
` below: revisions listed
`
`
`• Your o
`riginally proposed language to be added to the “Preparation of CUBICIN® for
`
`
`istration” section:
`
`Admin
`
`
`•
`
`
`Is to be replaced with the following language:
`
`
`
`
`
`
`
`"CUBICIN should not be used in conjunction with ReadyMED® elastomeric infusion
`pumps (Cardinal Health, Inc.). Stability studies of CUBICIN solutions stored in
`ReadyMED® elastomeric infusion pumps identified an impurity (2
`
`mercaptobenzothiazole) leaching from this pump system into the CUBICIN solution."
`
`(b)
`
`
`
`(4
`
`)
`
`
`
`NDA 21-572/S-021
`Page 2
`
`
`As soon as possible, but no later than 14 days from the date of this letter, please submit the content of
`labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format as described at
`http://www.fda.gov/oc/datacouncil/spl.html that is identical to the label submitted June 27, 2008 (with
`the exception of the above listed minor editorial revisions). Upon receipt, we will transmit that version
`to the National Library of Medicine for public dissemination. For administrative purposes, designate
`this submission "SPL for approved supplement NDA 21-572/S-021.”
`
` If you issue a letter communicating important information about this drug product (i.e., a “Dear Health
`
`
`Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to
`the following address:
`
`
`
`
`
`
`
`
`
`
` MEDWATCH
`
`
`
` Food and Drug Administration
`Suite 12B05
`
` 5600 Fishers Lane
`
`
`Rockville, MD 20857
`
`
`
`We remind you that you must comply with reporting requirements for an approved NDA (21 CFR
`
`
`314.80 and 314.81).
`
`If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301)
`
`796-0702.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Sincerely,
`
`
` {See appended electronic signature page}
`
`Sumathi Nambiar, MD, MPH
`
`
`
` Deputy Director for Safety
`Division of Anti-Infective and Ophthalmology Products
`
` Office of Antimicrobial Products
` Center for Drug Evaluation and Research
`
`
`
`
`
`
`
`---------------------------------------------------------------------------------------------------------------------
`This is a representation of an electronic record that was signed electronically and
`this page is the manifestation of the electronic signature.
`---------------------------------------------------------------------------------------------------------------------
`/s/
`
`---------------------
`Sumathi Nambiar
`
`2/10/2009 03:52:47 PM
`
`
`